Proprietary AI analyst is now available
- Public Comps
- Smith & Nephew
Smith & Nephew Valuation Multiples
Discover Smith & Nephew's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Penumbra, Fisher & Paykel, Olympus, Medpace and more.
Smith & Nephew Overview
About Smith & Nephew
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Founded
1937
HQ

Employees
17.3K
Website
Financials (LTM)
EV
$15B
Valuation Multiples
Start free trialSmith & Nephew Financials
Smith & Nephew reported last 12-month revenue of $6B and EBITDA of $2B.
In the same LTM period, Smith & Nephew generated $4B in gross profit, $2B in EBITDA, and $911M in net income.
Revenue (LTM)
Smith & Nephew P&L
In the most recent fiscal year, Smith & Nephew reported revenue of $6B and EBITDA of $2B.
Smith & Nephew is profitable as of last fiscal year, with gross margin of 68%, EBITDA margin of 26%, and net margin of 14%.
Financial data powered by Morningstar, Inc.
Smith & Nephew Stock Performance
Smith & Nephew has current market cap of $13B, and enterprise value of $15B.
Market Cap Evolution
Smith & Nephew's stock price is $14.88.
Smith & Nephew share price decreased by 0.4% in the last 30 days, and increased by 0.1% in the last year.
Smith & Nephew has an EPS (earnings per share) of $1.04.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $15B | $13B | 1.4% | -0.4% | -7.5% | 0.1% | $1.04 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSmith & Nephew Valuation Multiples
Smith & Nephew trades at 2.4x EV/Revenue multiple, and 9.3x EV/EBITDA.
EV / Revenue (LTM)
Smith & Nephew Financial Valuation Multiples
As of June 5, 2026, Smith & Nephew has market cap of $13B and EV of $15B.
Smith & Nephew has a P/E ratio of 13.9x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Smith & Nephew Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Smith & Nephew Margins & Growth Rates
Smith & Nephew grew revenue by 7% and EBITDA by 9% in the last fiscal year.
In the most recent fiscal year, Smith & Nephew reported gross margin of 68%, EBITDA margin of 26%, and net margin of 14%.
Smith & Nephew Margins
Smith & Nephew Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Smith & Nephew Operational KPIs
Smith & Nephew's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Smith & Nephew's Rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Smith & Nephew's Rule of X is 43% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Smith & Nephew Competitors
Smith & Nephew competitors include Penumbra, Fisher & Paykel, Olympus, Medpace, Cooper Companies, Align Technology, United Imaging, Zydus Lifesciences, Fresenius Medical Care and Coloplast.
Most Smith & Nephew public comparables operate across Medical Devices, Medical Supplies, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 8.7x | 8.2x | 46.7x | 44.0x | |||
| 9.2x | 9.1x | 26.6x | 26.4x | |||
| 2.1x | 2.0x | 9.0x | 11.7x | |||
| 5.0x | 4.8x | 22.3x | 21.6x | |||
| 3.5x | 3.4x | 11.3x | 10.8x | |||
| 2.8x | 2.7x | 10.3x | 9.9x | |||
| 6.1x | 5.7x | 33.3x | 32.4x | |||
| 4.2x | 4.1x | 13.5x | 15.8x | |||
This data is available for Pro users. Sign up to see all Smith & Nephew competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Smith & Nephew
Smith & Nephew has acquired 14 companies to date.
Last acquisition by Smith & Nephew was on January 12th 2026. Smith & Nephew acquired Integrity Orthopaedics for $450M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Smith & Nephew
| Description | Integrity Orthopaedics is a developer of soft tissue repair devices for rotator cuff surgeries. Based in Texas, the company markets the Integrity Anchor, a suture system providing 1,500N knot strength and biologic coatings to reduce re-tear rates by 25%. FDA-cleared in 2022, it deploys in 200 ORs nationwide with broad fixation across tendon footprints. | CartiHeal is a Herzliya-headquartered medical device company pioneering cartilage regeneration implants. The Agili-C scaffold, implanted arthroscopically, promotes hyaline cartilage formation in knee defects without cells or growth factors. FDA-approved in 2023 following pivotal trials showing superiority over microfracture in 261 patients. | Engage Surgical is a Salt Lake City-based orthopedics firm owning the only FDA-cleared cementless unicompartmental knee system in the US market. The Engage Partial Knee features a titanium plasma spray coating for biological fixation, used in medial and lateral compartment replacements. Surgeons implant it via minimally invasive techniques, with clinical data showing 98% survivorship at five years. Launched in 2019, the system addresses wear issues in cemented alternatives for active patients. | Integra LifeSciences Extremity Orthopaedics unit is a Plainsboro, New Jersey-based division developing orthopedic implants and instruments for foot, ankle, hand, and wrist procedures. The portfolio features the Puregenvi collagen matrix for tendon protection and the Infuse bone graft system. Its R&D pipeline advances a next-generation shoulder replacement system alongside extremity reconstruction devices. The unit supplies hospitals and surgery centers throughout North America and Europe. | |
| HQ Country | |||||
| HQ City | Minneapolis, MN | Kfar Saba | Orlando, FL | Plainsboro, NJ | |
| Deal Date | 12 Jan 2026 | 22 Nov 2023 | 19 Jan 2022 | 29 Sep 2020 | |
| Valuation | $450M | $330M | $135M | $240M | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Smith & Nephew acquisitions and their M&A valuation multiples. Start Free Trial | |||||
Investments by Smith & Nephew
Smith & Nephew has invested in 4 companies to date.
Latest investment by Smith & Nephew was on January 25th 2023. Smith & Nephew invested in Miach Orthopaedics in their $30M Series B round (EV/Revenue multiple available to Pro users).
Latest Investments by Smith & Nephew
| Description | Miach Orthopaedics is a Westborough-headquartered medical device company founded in 2016 developing the Bridge-Enhanced ACL Repair implant. This bio-engineered scaffold promotes native tissue regeneration as an alternative to autografts for anterior cruciate ligament injuries. | Trice Medical is a Pennsylvania-based developer of camera-enabled orthopedic diagnostic devices including the SeeTrue needle and miin system for in-office visualization of joints and tissues. Founded in 2011, the company equips physicians with single-use, integrated tools that deliver immediate imaging, reducing reliance on MRI and lowering procedure costs for patients with musculoskeletal conditions. | Trice Medical is a Pennsylvania-based developer of camera-enabled orthopedic diagnostic devices including the SeeTrue needle and miin system for in-office visualization of joints and tissues. Founded in 2011, the company equips physicians with single-use, integrated tools that deliver immediate imaging, reducing reliance on MRI and lowering procedure costs for patients with musculoskeletal conditions. | - | |
| HQ Country | |||||
| HQ City | Boston, MA | Philadelphia, PA | Philadelphia, PA | - | |
| Deal Date | 25 Jan 2023 | 14 Jan 2019 | 6 Jun 2017 | 1 Dec 2016 | |
| Round | Series B | Series C | Series C | Series A | |
| Raised | $30M | $18M | $19M | $7M | |
| Investors | Amzak Health Investors; DSM Venturing; Endeavour Vision; NFL Players Association; Sectoral Asset Management; Smith & Nephew | BioStar Capital; Charter Capital Partners; HealthQuest Capital; Municipal Employee Retirement System; Safeguard Scientifics; Smith & Nephew | BioStar Capital; HealthQuest Capital; Safeguard Scientifics; Smith & Nephew | HealthpointCapital; Johnson & Johnson Robotics and Digital Solutions; Smith & Nephew; Triventures | |
| Valuation | undisclosed | undisclosed | undisclosed | undisclosed | |
| EV/Revenue | |||||
| EV/EBITDA | |||||
This data is available for Pro users. Sign up to see all Smith & Nephew investments and their VC round multiples. Start Free Trial | |||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Smith & Nephew
| When was Smith & Nephew founded? | Smith & Nephew was founded in 1937. |
| Where is Smith & Nephew headquartered? | Smith & Nephew is headquartered in United Kingdom. |
| How many employees does Smith & Nephew have? | As of today, Smith & Nephew has over 17K employees. |
| Who is the CEO of Smith & Nephew? | Smith & Nephew's CEO is Deepak S. Nath. |
| Is Smith & Nephew publicly listed? | Yes, Smith & Nephew is a public company listed on London Stock Exchange. |
| What is the stock symbol of Smith & Nephew? | Smith & Nephew trades under SN. ticker. |
| When did Smith & Nephew go public? | Smith & Nephew went public in 1951. |
| Who are competitors of Smith & Nephew? | Smith & Nephew main competitors include Penumbra, Fisher & Paykel, Olympus, Medpace, Cooper Companies, Align Technology, United Imaging, Zydus Lifesciences, Fresenius Medical Care, Coloplast. |
| What is the current market cap of Smith & Nephew? | Smith & Nephew's current market cap is $13B. |
| What is the current revenue of Smith & Nephew? | Smith & Nephew's last 12 months revenue is $6B. |
| What is the current revenue growth of Smith & Nephew? | Smith & Nephew revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of Smith & Nephew? | Current revenue multiple of Smith & Nephew is 2.4x. |
| What is the current EBITDA of Smith & Nephew? | Smith & Nephew's last 12 months EBITDA is $2B. |
| What is Smith & Nephew's EBITDA margin? | Smith & Nephew's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Smith & Nephew? | Current EBITDA multiple of Smith & Nephew is 9.3x. |
| What is the current FCF of Smith & Nephew? | Smith & Nephew's last 12 months FCF is $784M. |
| What is Smith & Nephew's FCF margin? | Smith & Nephew's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Smith & Nephew? | Current FCF multiple of Smith & Nephew is 19.7x. |
| How many companies Smith & Nephew has acquired to date? | As of June 2026, Smith & Nephew has acquired 14 companies. |
| What was the largest acquisition by Smith & Nephew? | $2B acquisition of Arthrocare on 3rd February 2014 was the largest M&A Smith & Nephew has done to date. |
| What companies Smith & Nephew acquired? | Smith & Nephew acquired Arthrocare, Osiris Therapeutics, Integrity Orthopaedics, CartiHeal, Blue Belt Technologies, Integra LifeSciences (extremity orthopaedics unit), Rotation Medical, Tusker Medical, Engage Surgical, Leaf Healthcare, and 4 other companies. |
| In how many companies Smith & Nephew has invested to date? | As of June 2026, Smith & Nephew has invested in 4 companies. |
| What was the last Smith & Nephew investment? | On 25th January 2023 Smith & Nephew invested in Miach Orthopaedics, participating in a $30M Series B round, alongside Amzak Health Investors, DSM Venturing, Endeavour Vision, NFL Players Association, and Sectoral Asset Management. |
| In what companies Smith & Nephew invested in? | Smith & Nephew invested in Miach Orthopaedics, Trice Medical, OrthoSpace, and Michelson Diagnostics. |
See public comps similar to Smith & Nephew
Lists including Smith & Nephew
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

